Posts in Uncategorized

Excipients, Solvents and Elemental Impurities: Controlling the Formulation in Module 3

The active substance attracts most attention, but excipients, solvents and metals in the formulation are reviewed just as closely, and each has its own place[…]

Module 1 for Greece: What the National Part of the Dossier Must Contain

Modules 2 to 5 are harmonised, but Module 1 is where national requirements live, and for Greece it is where many otherwise complete dossiers get[…]

Writing the Quality Overall Summary: Module 2.3 as the Assessor’s Roadmap

Assessors usually read Module 2 first, and a weak Quality Overall Summary shapes how they read everything behind it. What Module 2 contains Module 2[…]

Nitrosamine Risk in the Dossier: Where It Sits in Module 3 and What Triggers a Variation

Nitrosamine risk management is no longer a standalone project; it is part of the quality dossier, and any change to the process, packaging or supplier[…]

Process Validation in Module 3: Traditional, Continuous and Hybrid Approaches

Regulators need to know the manufacturing process is under control, but the EU guideline does not require every product to be validated in the same[…]

Container Closure Systems in Module 3.2.P.7: Plastic Packaging and Leachables

The container closure system is part of the product, and for liquids, injectables and inhalation products it can be as critical to quality as the[…]

Analytical Procedures in the Dossier: What ICH Q2(R2) and Q14 Change

The revised ICH Q2(R2) and the new ICH Q14 move analytical procedures from a one-off validation exercise to a lifecycle that starts at development and[…]

Setting Drug Product Specifications: Release Limits, Shelf-Life Limits, Justification

A specification is not a list of tests copied from a pharmacopoeia; in the dossier it is a set of tests, methods and limits that[…]

Active Substance Routes in Module 3.2.S: Full Data, CEP or ASMF

Section 3.2.S of the dossier can be filled in three different ways, and the route you choose determines who controls the data, who can answer[…]

Hospital Formularies and E-Prescription: Where Access Is Decided After Reimbursement

Reimbursement is necessary for access, but it is not sufficient. A medicine can be listed and priced and still reach few patients, because prescribing is[…]

1 … 13 14 15 16 17 … 26